Monographie - Trastuzumab

Pēdējā atjaunošana :
19/11/2024

Trastuzumab

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Herceptin	Amerikas Savienotās Valstis, Apvienotie Arābu Emirāti, Argentīna, Austrālija, Austrija, Beļģija, Brazīlija, Čīle, Dānija, Ēģipte, Ekvadora, Francija, Grieķija, Holande, Irāna, Īrija, Islande, Itālija, Japāna, Jaunzēlande, Kanāda, Kolumbija, Lielbritānija, Luksemburga, Malaizija, Maroka, Meksika, Norvēģija, Peru, Polija, Portugāle, Rumānija, Saūda Arābija, Somija, Spānija, Šveice, Turcija, Ungārija, Vācija, Zviedrija
Herclon	Peru
Hertraz	Čīle
Herzuma	Amerikas Savienotās Valstis, Beļģija, Francija, Lielbritānija, Spānija, Vācija
Kanjinti	Beļģija, Lielbritānija, Spānija, Vācija
Trastuzumab Baxter	Jaunzēlande
Trazimera	Lielbritānija

Literatūras saraksts : Trastuzumab

	tips	publicēšana
2296	Laboratorija	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2975	plakāts	Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C. In-Use stability of herceptin for subcutaneous injection with different administration materials. ESCP 2014 2014
3077	Laboratorija	Trastuzumab (Herceptin®) – Summary of Product Characteristics Roche 2019
3113	Grāmata	Herceptin Compendium Suisse des m?dicaments 2010
3258	Žurnāls	Kaiser J, Krämer I. Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags. Int J Pharm Compound 2011 ; 15, 6 : 515-520.
3343	plakāts	Vieillard V, da Silva R, Astier A, Paul M. Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C. ECOP Congress, Budapest, Hungary 2012
3366	Žurnāls	Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 2012 ; DOI 10.1002 / jps.23403
3386	Žurnāls	Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. Long-term physico-chemical stability of diluted trastuzumab. Int J Pharm 2013 ; 448: 101-104.
3647	Laboratorija	Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics Roche 2019
3849	Žurnāls	Pabari R.M, Ryan B, Ahmad W, Ramtoola Z. Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions. Curr Pharm Biotech 2013 ; 14, 2: 220-225.
4163	Žurnāls	Nalenz H, K?pf E, Dietel E. Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags. Int J Pharm Compound 2018 22;5:417-423
4191	Žurnāls	Vieillard V, Astier A, Paul M. Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures. GaBI Journal 2018
4194	Žurnāls	Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y. In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion. Bio Drugs 2018 32;619-625
4271	Žurnāls	Yun J, Kim J, Chung J, Hwang S-J, Park S-J. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties Adv Ther 2019
4396	Žurnāls	Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions. GaBI Journal 2020 ; 9, 1:
4477	Žurnāls	Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions. GaBI Journal 2020 ; 9, 1: 5-13.
4493	Žurnāls	Le Guyader G, Vieillard V, Paul M. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion. J Oncol Pharm Practice 2020
4649	Žurnāls	Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J. Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices. GaBI Journal 2021 ; 10, 4
4754	Žurnāls	Weiser S, Burns C, Zartler E Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions. J Oncol Pharm Practice 2023 ;29,3:

Mentions Légales